For regulatory details on semaglutide, the Wegovy prescribing information outlines warnings regarding thyroid C-cell tumors, pancreatitis, and gallbladder disease
These pens clearly display the prescribed dose in milligrams (mg) on a simple dial and not units, allowing straightforward subcutaneous administration once weekly into the abdomen, thigh, or upper arm without needing syringes. Never attempt to extract semaglutide from Ozempic pens using syringes, as the pens internal design and different concentrations can lead to a significant risk of dosing errors often 5 to 20 times the intended amount due to misreading syringe markings or misunderstanding volume
Phase II trials average USD 7-30 million, with oncology Phase IIa proof-of-concept trials in biomarker-defined populations often landing at the lower end
Most clinical trials studied 68 weeks of treatment, but many people continue indefinitely
The medication dose is already at the planned level Many people see their strongest results once they reach their maintenance dose